Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Navidea Biopharmaceuticals to Present at Biotech Showcase 2018

Navidea Biopharmaceuticals,Inc.
Posted on: 19 Dec 17

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it will be presenting at the Biotech Showcase in San Francisco, CA being held on January 8-10, 2018. Dr. Michael Goldberg, Chief Executive Officer of Navidea, will be giving a presentation and meeting with investors.

Event: Biotech Showcase™
Presentation Date: Monday, January 8, 2018
Presentation Time: 10:00 am PT
Location: Hilton San Francisco Union Square, San Francisco, CA

For investors attending the Biotech Showcase, please contact Navidea Investor Relations to schedule a meeting with management at tpatel@edisongroup.com.

The presentation will be webcast live and remain available for 90 days following the presentation. To access the webcast, please visit the Investors presentations tab of the Investors section of the Navidea website at www.navidea.com.

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc 99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. The development activities of the Manocept immunotherapeutic platform are being conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics, Inc. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts.

For more information, please visit www.navidea.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171219006195/en/

Business Wire
www.businesswire.com

Last updated on: 19/12/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.